Drug Pricing
Commentary
Read the latest about VP Harris' healthcare platform
Harris commits to worst of Biden healthcare policies
One proposal Harris has explicitly backed would enshrine President Joe Biden’s enhanced Obamacare subsidies, which are slated to expire in 2025. “Republicans want to let those credits expire, increasing premiums,” the Democratic platform asserts. “Democrats will fight to make them permanent.” Read the full article at the Washington Examiner
Sally C. Pipes
August 24, 2024
Commentary
This Bipartisan Bill Would Upend America’s Pharmaceutical Industry
Vice President Kamala Harris and Minnesota Governor Tim Walz have pivoted hard to the center in recent weeks in their bid for the White House. But their records indicate that they’d launch even more government intervention in the healthcare market. Harris was the most progressive member of the Senate during ...
Sally C. Pipes
August 19, 2024
Blog
Read about Biden drug price control plan
The Damage from Price Controls on Pharmaceuticals Begins
The federal government has announced the long-awaited results from the 2022 Inflation Reduction Act’s (IRA) drug price negotiations.[1] The Biden Administration has been crowing that they have achieved “a historic moment that will help lower prescription drug prices for millions of people across America.” Nothing could be further from the ...
Sally Pipes and Wayne Winegarden
August 15, 2024
Commentary
Scope-of-practice laws put patients in the crosshairs
New research appears to have found the proverbial “free lunch” economists have long been searching for. States that grant nurse practitioners “full practice authority” — that authorize them to provide care independently, without the supervision of a physician or other provider — reduce total healthcare costs for people with diabetes ...
Sally C. Pipes
August 13, 2024
Commentary
Pending Government Drug Pricing Will Harm Seniors’ Care And Budgets
Any day now, the Biden administration will publish the prices it has set for ten drugs covered by Medicare’s Part D prescription drug benefit. These price controls will provide “meaningful financial relief for millions of people with Medicare,” administration officials say. Many seniors are about to see just how false that ...
Sally C. Pipes
August 12, 2024
Commentary
The Anti-Competitive Middlemen Harming Pharmacies And Patients
Astonishing drug innovations are improving the lives of patients including those living with cancer and autoimmune disorders. These innovations also expose the payment system’s fundamental flaws. The Federal Trade Commission’s (FTC) recently released interim report on pharmacy middlemen demonstrates that these flaws impose a high cost on patients and neighborhood pharmacies. These ...
Wayne Winegarden
August 6, 2024
Commentary
Read the latest on pharmaceutical benefit managers
Legislation Urgently Needed to Rein In Pharmacy Benefit Mgrs.
The U.S. House Committee on Oversight and Accountability held a hearing last month with the CEOs of the nation’s three largest pharmacy benefit managers: CVS Caremark, Express Scripts, and OptumRx. The hearing coincided with a new report from the committee on the outsized role these prescription-drug middlemen play in determining what people pay for ...
Sally C. Pipes
August 5, 2024
Commentary
Read the latest on the 340B Drug Pricing Program
Reforming 340B to Serve the Interests of Patients, Not Institutions
By Anthony M. DiGiorgio, DO, MHA and Wayne Winegarden, PhD Enacted by the US Congress in 1992 to help entities serving lower-income and uninsured patients stretch their resources, the 340B Drug Pricing Program mandated drug companies give large discounts to covered entities (CEs). Judging the program on its outcomes, not its intentions, ...
Pacific Research Institute
July 26, 2024
Commentary
We’re Closer Than Ever To Beating Alzheimer’s. Price Controls Could Change That.
Earlier this month, the U.S. Food and Drug Administration approved donanemab, a novel treatment for Alzheimer’s disease that Eli Lilly will sell under the brand name Kisunla. The drug targets amyloid, a type of protein that builds up in the brains of people with the disease. It was shown to slow the ...
Sally C. Pipes
July 22, 2024
Commentary
Fix the 340B Program to Increase Access to Medicine
House lawmakers recently introduced legislation that would at last repair a program meant to provide low-income Americans with affordable medicine. In theory, the federal 340B Program, named after the section of the 1992 law establishing it, allows hospitals serving underprivileged groups to buy medications at steep discounts. The idea was ...
Sally C. Pipes
June 27, 2024
Read the latest about VP Harris' healthcare platform
Harris commits to worst of Biden healthcare policies
One proposal Harris has explicitly backed would enshrine President Joe Biden’s enhanced Obamacare subsidies, which are slated to expire in 2025. “Republicans want to let those credits expire, increasing premiums,” the Democratic platform asserts. “Democrats will fight to make them permanent.” Read the full article at the Washington Examiner
This Bipartisan Bill Would Upend America’s Pharmaceutical Industry
Vice President Kamala Harris and Minnesota Governor Tim Walz have pivoted hard to the center in recent weeks in their bid for the White House. But their records indicate that they’d launch even more government intervention in the healthcare market. Harris was the most progressive member of the Senate during ...
Read about Biden drug price control plan
The Damage from Price Controls on Pharmaceuticals Begins
The federal government has announced the long-awaited results from the 2022 Inflation Reduction Act’s (IRA) drug price negotiations.[1] The Biden Administration has been crowing that they have achieved “a historic moment that will help lower prescription drug prices for millions of people across America.” Nothing could be further from the ...
Scope-of-practice laws put patients in the crosshairs
New research appears to have found the proverbial “free lunch” economists have long been searching for. States that grant nurse practitioners “full practice authority” — that authorize them to provide care independently, without the supervision of a physician or other provider — reduce total healthcare costs for people with diabetes ...
Pending Government Drug Pricing Will Harm Seniors’ Care And Budgets
Any day now, the Biden administration will publish the prices it has set for ten drugs covered by Medicare’s Part D prescription drug benefit. These price controls will provide “meaningful financial relief for millions of people with Medicare,” administration officials say. Many seniors are about to see just how false that ...
The Anti-Competitive Middlemen Harming Pharmacies And Patients
Astonishing drug innovations are improving the lives of patients including those living with cancer and autoimmune disorders. These innovations also expose the payment system’s fundamental flaws. The Federal Trade Commission’s (FTC) recently released interim report on pharmacy middlemen demonstrates that these flaws impose a high cost on patients and neighborhood pharmacies. These ...
Read the latest on pharmaceutical benefit managers
Legislation Urgently Needed to Rein In Pharmacy Benefit Mgrs.
The U.S. House Committee on Oversight and Accountability held a hearing last month with the CEOs of the nation’s three largest pharmacy benefit managers: CVS Caremark, Express Scripts, and OptumRx. The hearing coincided with a new report from the committee on the outsized role these prescription-drug middlemen play in determining what people pay for ...
Read the latest on the 340B Drug Pricing Program
Reforming 340B to Serve the Interests of Patients, Not Institutions
By Anthony M. DiGiorgio, DO, MHA and Wayne Winegarden, PhD Enacted by the US Congress in 1992 to help entities serving lower-income and uninsured patients stretch their resources, the 340B Drug Pricing Program mandated drug companies give large discounts to covered entities (CEs). Judging the program on its outcomes, not its intentions, ...
We’re Closer Than Ever To Beating Alzheimer’s. Price Controls Could Change That.
Earlier this month, the U.S. Food and Drug Administration approved donanemab, a novel treatment for Alzheimer’s disease that Eli Lilly will sell under the brand name Kisunla. The drug targets amyloid, a type of protein that builds up in the brains of people with the disease. It was shown to slow the ...
Fix the 340B Program to Increase Access to Medicine
House lawmakers recently introduced legislation that would at last repair a program meant to provide low-income Americans with affordable medicine. In theory, the federal 340B Program, named after the section of the 1992 law establishing it, allows hospitals serving underprivileged groups to buy medications at steep discounts. The idea was ...